PMID- 29922761
OWN - NLM
STAT- MEDLINE
DCOM- 20190422
LR  - 20190422
IS  - 1842-1121 (Electronic)
IS  - 1841-8724 (Linking)
VI  - 27
IP  - 2
DP  - 2018 Jun
TI  - Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C 
      patients with genotype 2 and 3: a comprehensive analysis of 18 randomized 
      controlled trials.
PG  - 159-168
LID - 10.15403/jgld.2014.1121.272.sof [doi]
AB  - BACKGROUND AND AIM: Sofosbuvir is a hepatitis C virus (HCV) NS5B polymerase 
      inhibitor. The objective of this study was to explore the efficacy and safety of 
      sofosbuvir for HCV genotype (GT) 2 and 3 infected patients. METHOD: We searched 
      randomized controlled trials (RCTs) which analyzed the efficacy and safety of 
      sofosbuvir-containing regimens for HCV GT 2/3 infected patients and collected 
      data. The endpoints were sustained virological response 12- and 24-weeks after 
      the cessation of therapy (SVR12 and SVR24), the adverse events (AEs) and the 
      severe adverse events (SAEs). RESULTS: Eighteen trials comprising 2,975 HCV GT 
      2/3 infected patients were included. The pooled estimate SVR12, SVR24, AEs and 
      SAEs rates were 84.6% (95% CI: 83.2-86.0), 83.7% (95% CI: 82.0-85.2), 83.8 (95% 
      CI: 82.3-85.3) and 3.9 (95% CI: 3.2-4.8). The SVR12 rate of sofosbuvir-containing 
      regimens for HCV GT 2 infection was higher than that for HCV GT 3 infection 
      (95.7% vs. 80.8%). The sofosbuvir combined with velpatasvir (with or without 
      ribavirin) regimen presented a higher SVR12 rate and lower AEs rate than the 
      sofosbuvir combined with ribavirin (with or without peg-IFN) regimen (94.9% vs. 
      80.7% for SVR12 rate; 69.3% vs. 87.7% for AEs rate). CONCLUSIONS: The 
      sofosbuvir-containing regimens in patients with HCV GT 2 infection have better 
      efficacy than in patients with HCV GT 3 infection.
FAU - Fan, Haozhi
AU  - Fan H
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, R.P.China.
FAU - Huang, Peng
AU  - Huang P
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing;Institute of Epidemiology and Microbiology, Huadong 
      Research Institute for Medicine and Biotechnics, Nanjing, R.P.China.
FAU - Tian, Ting
AU  - Tian T
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, R.P.China.
FAU - Wu, Jingjing
AU  - Wu J
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, R.P.China.
FAU - Xia, Xueshan
AU  - Xia X
AD  - Faculty of Life Science and Technology, Kunming University of Science and 
      Technology, Yunnan, R.P.China.
FAU - Feng, Yue
AU  - Feng Y
AD  - Faculty of Life Science and Technology, Kunming University of Science and 
      Technology, Yunnan, R.P.China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Basic and Community Nursing, School of Nursing, Nanjing Medical 
      University, Nanjing, R.P.China.
FAU - Yu, Rongbin
AU  - Yu R
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, R.P.China.
FAU - Zhang, Yun
AU  - Zhang Y
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing; Institute of Epidemiology and Microbiology, Huadong 
      Research Institute for Medicine and Biotechnics, Nanjing, R.P.China.
FAU - Yue, Ming
AU  - Yue M
AD  - Department of Infectious Diseases, the First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, P.R. China. njym08@163.com.
LA  - eng
PT  - Meta-Analysis
PL  - Romania
TA  - J Gastrointestin Liver Dis
JT  - Journal of gastrointestinal and liver diseases : JGLD
JID - 101272825
RN  - 0 (Antiviral Agents)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Antiviral Agents/adverse effects/pharmacology/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/drug effects/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Sofosbuvir/adverse effects/pharmacology/*therapeutic use
MH  - Sustained Virologic Response
EDAT- 2018/06/21 06:00
MHDA- 2019/04/23 06:00
CRDT- 2018/06/21 06:00
PHST- 2018/06/21 06:00 [entrez]
PHST- 2018/06/21 06:00 [pubmed]
PHST- 2019/04/23 06:00 [medline]
AID - 8 [pii]
AID - 10.15403/jgld.2014.1121.272.sof [doi]
PST - ppublish
SO  - J Gastrointestin Liver Dis. 2018 Jun;27(2):159-168. doi: 
      10.15403/jgld.2014.1121.272.sof.